Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization. Therefore, the pharmaceutical industry is on the lookout for tools / methods that can help mitigate this challenge. Amidst the current initiatives to develop therapeutic interventions with improved bioavailability, nanoparticles have specifically captured the interest of researchers and drug developers, given their ability to act as drug carriers for complex and highly promising therapeutics. As a matter of fact, recently many drug developers have initiated formulating novel therapeutic interventions that utilize nanoparticles as a major component (nanomedicines).
Nanoparticles can be defined as particles that fall within the size range of 1 to 100 nanometers (nm) and are invisible to the unaided human eye. Role of nanoparticles has been well established across various markets, such as healthcare, paint, consumer products (includingsunscreens, cosmetics), aerospace and glass industries. Some of the applications of nanoparticle in the field of healthcare are depicted below.
Given their numerous applications, nanoparticles are being utilized across different sectors within the healthcare domain. However, manufacturing of these particles is a major challenge for players engaged in the industry. Some of these challenges include stability of nanocluster, thermal noise, energy dissipation, high energy requirements, high reproducibility and environmental safety. Hence, many pharmaceutical companies outsource manufacturing of nanoparticles to third party organizations, called as contract manufacturers. Variety of services provided by contract manufacturers are as follows:
More than 50 players claim to offer nanoparticle contract manufacturing across the globe
Although players that offer nanoparticle contract manufacturing are present across the globe, most of them (~55%) are headquartered in North America, followed by Europe. Pasted below is a donut chart, showing the regional distribution of companies offering contract manufacturing services for nanoparticles.
Nearly 55 collaborations and partnership have been inked in this domain since 2015
Over the years, players offering nanoparticle contract manufacturing have actively collaborated with several players across the globe. Of these, 90% of the partnerships have been inked with industry players. In addition, in order to address the cell boundary challenge associated with the mRNA COVID-19 vaccines, majority of the deals in this industry have been inked for manufacturing lipid nanoparticles, required to envelop and deliver the mRNA (over 55%).
It is worth highlighting that over 80% of the partnerships with industry players have been inked by CDMOs. Pasted below is a donut chart, showing the distribution by type of partner and type of nanoparticle(s) manufactured by companies offering contract manufacturing services for nanoparticles.
Hence, given the fact that several new players have entered the domain in the last decade, who are actively collaborating with other industry players to expand the global reach of their proprietary products, the nanoparticle contract manufacturing market is expected to increase at a high CAGR. In fact, the market opportunity is expected to be boosted further as an impact of COVID-19.
For further information on this domain, check out the report –